MYCOPHENOLATE SODIUM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MYCOPHENOLATE SODIUM (MYCOPHENOLATE SODIUM).
Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.
| Metabolism | Mycophenolate sodium is a prodrug that is rapidly hydrolyzed in the gastrointestinal tract to the active metabolite mycophenolic acid (MPA). MPA is primarily metabolized by uridine diphosphate-glucuronosyltransferase (UGT) 1A9 to the inactive phenolic glucuronide (MPAG). A minor acyl glucuronide metabolite is also formed. MPAG is excreted in the urine and can be deconjugated back to MPA via enterohepatic recirculation. |
| Excretion | Mycophenolate sodium is excreted primarily in urine as mycophenolic acid (MPA) and its glucuronide metabolite (MPAG). Renal excretion accounts for approximately 87% of the dose, with <1% excreted as unchanged MPA. Fecal excretion represents about 6%. |
| Half-life | The terminal elimination half-life of mycophenolic acid is approximately 8-16 hours in healthy subjects and renal transplant patients. The half-life of the inactive glucuronide metabolite (MPAG) is longer (16-18 hours) and accumulates in renal impairment. |
| Protein binding | Mycophenolic acid is 97% bound to serum albumin. The glucuronide metabolite (MPAG) is 82% bound. |
| Volume of Distribution | The apparent volume of distribution of mycophenolic acid is approximately 3.6 L/kg, indicating extensive tissue distribution. This large Vd reflects high tissue binding and distribution into extravascular spaces. |
| Bioavailability | The oral bioavailability of mycophenolate sodium enteric-coated tablets is approximately 72% relative to intravenous mycophenolate mofetil. Food reduces peak concentration (Cmax) by 30-50% but does not significantly affect total area under the curve (AUC). |
| Onset of Action | For oral enteric-coated tablets, peak plasma concentrations are achieved at 1.5-2.5 hours post-dose. The onset of immunosuppressive effect occurs within hours as MPA inhibits inosine monophosphate dehydrogenase (IMPDH), but clinical efficacy in transplant rejection typically requires several days to weeks of continuous therapy. |
| Duration of Action | The pharmacodynamic effect of MPA (IMPDH inhibition) persists for the dosing interval (typically 12 hours). For prevention of transplant rejection, continuous exposure is required; duration of action is not applicable as a single dose. |
720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | For GFR 15-29 mL/min/1.73 m2: do not exceed 720 mg orally twice daily. For GFR <15 mL/min/1.73 m2: no data; use with caution. No adjustment for GFR >=30 mL/min/1.73 m2. |
| Liver impairment | No specific dose adjustment guidelines for Child-Pugh class A, B, or C. Use with caution in severe hepatic impairment due to limited data. |
| Pediatric use | Approved for pediatric renal transplant patients >=2 years: 400 mg/m2 orally twice daily (up to a maximum of 720 mg twice daily). For bone marrow transplant patients >=2 years: 400 mg/m2 orally twice daily, starting 24 hours after graft infusion. |
| Geriatric use | No specific dose adjustment recommended; elderly patients may have increased risk of adverse effects such as gastrointestinal hemorrhage and infections. Use the lowest effective dose and monitor renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MYCOPHENOLATE SODIUM (MYCOPHENOLATE SODIUM).
| Breastfeeding | Enters breast milk; M/P ratio not established. Potential for serious adverse effects in nursing infants (e.g., immunosuppression, gastrointestinal disturbances). Contraindicated during breastfeeding. |
| Teratogenic Risk | First trimester: High risk of structural malformations (e.g., cleft lip/palate, microtia, congenital heart defects) and spontaneous abortion. Second and third trimesters: Risk of oligohydramnios, intrauterine growth restriction, and preterm birth. Use is contraindicated in pregnancy unless no alternative. |
■ FDA Black Box Warning
Increased risk of congenital malformations and first-trimester pregnancy loss when used during pregnancy. Females of reproductive potential must be counseled about pregnancy prevention and planning. Mycophenolate can cause fetal harm when administered to a pregnant woman. Use is contraindicated in women of childbearing potential who are not using highly effective contraception.
| Serious Effects |
["Hypersensitivity to mycophenolate sodium, mycophenolic acid, or any component of the formulation","Women of childbearing potential not using highly effective contraception","Pregnancy (unless no suitable alternative immunosuppressant is available)"]
| Precautions | ["Immunosuppression: Increased susceptibility to infections, including opportunistic infections and reactivation of latent viruses (e.g., CMV, BK virus).","Lymphoproliferative disorders: Increased risk of post-transplant lymphoproliferative disorder (PTLD) and other malignancies.","Pregnancy: Associated with first-trimester pregnancy loss and congenital malformations; contraception counseling required.","Gastrointestinal events: Severe GI bleeding, perforation, and ulceration; monitor for symptoms.","Neutropenia: Can cause severe neutropenia; monitor complete blood counts regularly.","Vaccinations: Live vaccines should not be given during treatment; influenza vaccination may be less effective."] |
Loading safety data…
| Fetal Monitoring |
| Monitor immunosuppression parameters (lymphocyte count, immunoglobulins), renal function (serum creatinine, BUN), liver function tests, complete blood count, and signs of infection. Fetal monitoring: serial ultrasounds for growth and anatomy, amniotic fluid volume assessment. |
| Fertility Effects | May impair spermatogenesis in males (reversible) and cause ovarian failure in females; consult fertility specialist. Use effective contraception during therapy and for 6 weeks after discontinuation for females, 90 days for males. |